Indoleamine 2,3-dioxygenase 1 (IDO1)

Where the papers sit

10 papers from the last 6 months study Indoleamine 2,3-dioxygenase 1 (IDO1) directly · updated from PubMed 12 Oct 2026

• IDO1–Kynurenine Pathway Biology

  IDO1–kynurenine signaling is being pursued both as a cancer-immunotherapy target and as a regulator of tissue protection. Dual IDO1/TDO inhibitors, a miconazole analogue and BMS-986205 aim to counter tumor progression and immunosuppression. In contrast, pathway activation through AhR is associated with graft survival and bone homeostasis. METTL3, SHP-2 and apoptosis recur as mechanistic links, leaving context-dependent effects unresolved.

  6 papers · 60%

• Triple-Negative Breast Cancer Targets

  Computational drug discovery is prioritizing targets in triple-negative breast cancer, especially VEGFR2 and GSK3B. Schisandrin A is linked to immune-niche regulation and MDA-MB-231 tumor biology. Random-forest models, docking and molecular dynamics rank compounds and interactions. The proposed mechanisms remain chiefly computational and require experimental validation.

  2 papers · 20%

• Breast Cancer Immune Checkpoints

  Shikonin combined with mild photothermal therapy is being used to convert immune-cold breast tumors into sources of systemic antitumor immunity. Immunogenic cell death and remodeling of the tumor microenvironment are central endpoints. Broader work is expanding checkpoint concepts beyond PD-L1 to metabolic enzymes and immune receptors. How these targets translate into effective clinical combinations remains open.

  2 papers · 20%